Stock Image

Vascular Disruptive Agents for the Treatment of Cancer

Meyer, Tim (EDT)

0 ratings by Goodreads
ISBN 10: 1441966080 / ISBN 13: 9781441966087
Published by Springer 2010-09-10, 2010
New Condition: New Hardcover
From Chiron Media (Wallingford, United Kingdom)

AbeBooks Seller Since 02 August 2010 Seller Rating 4-star rating

Quantity Available: 3

Buy New
Price: 175.27 Convert Currency
Shipping: 9.32 From United Kingdom to U.S.A. Destination, rates & speeds
Add to basket

About this Item

Bookseller Inventory # NU-LBR-00717848

Ask Seller a Question

Bibliographic Details

Title: Vascular Disruptive Agents for the Treatment...

Publisher: Springer 2010-09-10

Publication Date: 2010

Binding: HARDCOVER

Book Condition: New

About this title

Synopsis:

Hard to Find book

From the Back Cover:

Tumour survival and growth is critically dependent on an independent blood supply. As such tumour vasculature presents an ideal target for cancer therapy that is widely applicable, accessible and genetically stable rendering it less prone to resistance. Two approaches have been explored for cancer therapy; firstly the prevention of new vessel formation with inhibitors of angiogenesis, and secondly the destruction of existing tumour blood vessels with so called vascular disruptive agents (VDAs). While the first approach appears to delay tumour progression, the second has the potential to cause massive cell death and tumour regression. It is the second approach of vascular targeting that is the focus of this book. Since the tubulin binding agent combretastatin, derived from the bark of the African bush willow, was discovered by George R Pettit to have antimitotic properties over twenty years ago, the field of vascular targeting has expanded steadily. Coincident with the preclinical and clinical development of these agents, there have been advances in our understanding of their mechanism of action and in the technology required to assess their effects. This book aims to provide a comprehensive account of the current state of the art. Preclinical target identification and validation are discussed and the optimum pre-clinical animal models described. The imaging modalities that can be used to assess the efficacy of these agents are examined and a comprehensive review of the clinical development of key drugs is provided. Finally, the recent research exploring rational combinations of VDAs with other agents is reviewed and the potential place of VDAs in the future of cancer therapy is critically appraised.

"About this title" may belong to another edition of this title.

Store Description

Visit Seller's Storefront

Terms of Sale:

TBA

Shipping Terms:

Shipping costs are based on books weighing 2.2 LB, or 1 KG. If your book order is heavy or oversized, we may contact you to let you know extra shipping is required.

List this Seller's Books

Payment Methods
accepted by seller

Visa Mastercard American Express